Welcome to Pharma and Biotech Patent Litigation 2025
This is Europe’s premier event for life sciences IP professionals. This January, join over 450 industry experts as we dive deep into the most pressing challenges and innovations in contentious IP law. Across three days of focused discussions and networking, you’ll gain valuable insights into the latest case law, regulatory updates, and strategic litigation approaches, while connecting with key stakeholders who drive the future of life sciences IP.
New for 2025
This year's summit will proudly host the industry's inaugural Women in IP workshop during our UPC Litigation Forum, featuring targeted workshop discussions. Additionally, we are introducing specialized and intimate litigation sessions tailored for the MedTech, large molecule, and small molecule sectors.
Why Should You Attend?
Elevate your patent litigation strategy by gaining insights into pressing legal challenges facing the life sciences sector. At this premier event, you'll dissect the first UPC decision on the merits, delve into the intricacies of SPCs and patentability issues, and explore the latest developments in cross-border case law and competition law.
Join Europe’s leading life science IP litigation professionals at the Beurs Van Berlage this January, where you'll engage in a cross-industry UPC Litigation Forum on January 20th, followed by a comprehensive summit focused on pharma and biotech patent litigation on January 21-22nd. This event offers a unique opportunity to forge essential commercial relationships with top stakeholders in the field, ensuring you're equipped to navigate the evolving landscape of life science IP litigation.
Highlights For 2025
Stay ahead of the curve with insights into the latest life science litigation, including cross-border cases, biosimilars, vaccines, and SPCs.
Gain actionable knowledge on the UPC’s impact on the life sciences sector, featuring industry-focused panels and a pre-event forum for practical, cross-industry discussions.
Engage in targeted, in-depth discussions with tracked sessions on MedTech, Large Molecule, and Small Molecule patent litigation.
Explore key updates and challenges in divisional patenting, PIs, second medical use, G2/21, and the Bolar exemption from top pharma and biotech IP specialists.
Gain unique insights into judicial perspectives through our global judges panel and the pre-event UPC Litigation Forum.
Here Is What Your Peers Envision For The 2025 Edition Of This Event
Loading videos...
LIFE SCIENCES PATENT ADVISORY BOARD
Dr. Leslie Fischer
Principal Patent Attorney
Sandoz
Leslie Fischer is a Principal Patent Attorney at Sandoz, who focuses on global IP strategy for biosimilars. Before joining Sandoz, Leslie was a patent attorney at Novartis Pharmaceuticals, where she worked for over a decade developing global patent portfolios for biologicals. Before joining the Novartis group, Leslie was an associate at Fitzpatrick Cella (NY) (now Venable). Leslie holds a J.D. from Rutgers University and a Ph.D. in Biochemistry from Thomas Jefferson University. Her scientific work appears in JCB, JBC, and Osteoarthritis & Cartilage. She speaks frequently at patent-related events and is an adjunct professor at Seton Hall Law School.
Christof Bull
Associate General Patent Counsel
UCB
Mathilde Rauline
Head of Greater Europe Patent Litigation
Sanofi
Mathilde is a European patent attorney, is qualified as a French patent attorney, and is admitted to the Paris bar.
She is head of Greater Europe patent litigation at Sanofi, after having been a patent litigator in private practice (mostly in the pharmaceutical field), and a patent attorney in the industry (Sanofi, Nestlé).
She has extensive experience in pharmaceutical and life-science patent litigation in France, at the EPO, in Europe, and in Eurasia.
Her expertise also comprises contractual matters, settlements, regulatory aspects, and the SPC regulation.
Lorenz Kallenbach
Senior Corporate Patent Counsel (Director)
Merck
Lorenz Kallenbach is a senior corporate patent counsel in the healthcare division of Merck KGaA. He is responsible for defining and executing the IP strategy for innovator projects. Including the assessment of the IP landscape, coordination of worldwide patent litigation, and portfolio development.
Before joining Merck, Lorenz worked in private practice. He is qualified as a German and European patent attorney.
Lorenz studied biochemistry and received a Ph.D. in the field of epigenetics.
Stephan Kutik
Senior Director, Intellectual Property
Genevant Sciences GmbH
Ewan Nettleton
Principal IP Counsel, Oncology Litigation
Novartis Pharma AG
Tessa M. Malamud-Cohen
Director, Patents, Global Intellectual Property
Ferring Pharmaceuticals
Paki Banky
Senior IP Counsel (IP Lead Cell & Gene)
Novartis
Corinna Sundermann
Senior Vice President Intellectual Property
Fresenius Kabi
Frank Landolt
Chief Counsel IP & Legal
Confo Therapeutics
Frank Landolt is Chief Counsel, Intellectual Property and Legal at Confo Therapeutics, a privately held biopharmaceutical start-up based in Ghent, Belgium specializing in GPCR-targeted therapeutics.
After studying chemistry and law at the University of Leiden in the Netherlands, Frank worked for almost ten years on pharmaceutical and biotechological patents and licensing in private practice in the Netherlands, where his clients included major pharmaceutical companies as well as some of the top biotech firms and research institutions in the Netherlands.
Prior to joining Confo in 2018, Frank worked for fifteen years in Ablynx N.V. (now a wholly owned Sanofi company), where he was a member of the management team and headed an integrated IP and legal group of four lawyers and five patent professionals. At Ablynx, Frank was involved in negotiating Ablynx’s strategic partnerships and licensing deals with AbbVie, Boehringer-Ingelheim, MSD, Merck-Serono, Novartis, Novo Nordisk, Sanofi and Wyeth.
From 2000 to 2004, Frank was director of IP and legal counsel at Devgen N.V. (now part of Syngenta), another Ghent-based biotechnology company, where he was involved in negotiating Devgen’s strategic collaborations with Sumitomo, Monsanto and DuPont Pioneer.
Frank is a Dutch and European patent attorney, and also holds a degree in business law from the University of Antwerp. He is a member of the Dutch association of patent attorneys (where he is a tutor for the professional qualification course), EPI and LES Benelux (where he is involved in the LES Licensing Course). He is a regular speaker on a range of topics relating to IP and licensing in the (bio)pharmaceutical sector. Frank was named as one of Managing IP’s ‘Corporate IP stars’ for four years in a row (2015-2018).
Guido Pontremoli
Vice President Global IP
Chiesi
Currently employed as global Head of the IP department-Patent at Chiesi Farmaceutici SpA, managing and coaching a team of experienced patent attorneys, patent searchers and administrators, working on the protection, enforcement, litigation and/or opposition of the Chiesi IP, aligned with business decisions.
Before joining Chiesi, I worked in IP groups of big pharma companies (GSK Vaccine, and Bracco Imaging) as senior patent attorney responsible for all the IP aspects concerning some key R&D projects. I also had experience as patent counsel in private practices, dealing with pharma, chemical and bio entities.
Graduated in chemistry from the Univ of Milan, with a PhD in medicinal chemistry and a post-doc experience in USA, I am qualified EPA and chartered Italian patent attorney.
Kristin Cooklin
Group Head IP Counsel
Recordati
Toni Santamaria
Vice President Intellectual Property
Adalvo
Toni has been leading the Intellectual Property team at Adalvo since 2021. He has more than 20 years of experience in different pharmaceutical companies where he has been involved in developing and implementing complex patent and data exclusivity litigation strategies for several generics and added value products, including leading parallel litigation cases in multiple European countries. He also has experience in patent and trademark prosecution.
Toni qualified as European Patent Attorney in 2010 and holds a PhD in Organic Chemistry.
Shohta Ueno
Assistant General Counsel - Dispute Resolution
Regeneron
Adrian Spillmann
Director of Intellectual Property
Valneva
Julia Pike
Global Head of IP
Sandoz
Since March 2020, Julia has been the Global Head of IP for Sandoz. In her previous roles with Sandoz, she has had a leading role in the first wave of US biosimilars litigation, including the first litigations on critical aspects of the governing legislation (the Biologics Price Competition and Innovation Act or BPCIA), culminating in the landmark US Supreme Court decision, Sandoz v Amgen.
Since leaving private practice at Corrs Chambers Westgarth, Julia has been in-house counsel for many years including at Mayne Pharma and Hospira Inc before joining Sandoz in 2008. While there, she has taken on roles in European public affairs and led Sandoz’s global IP litigation function as Global Head of IP Litigation. Through those roles, she has maintained a keen interest in IP strategy and litigation worldwide, including cases arising under the Hatch-Waxman and BPCIA legislation in the US, PM(NOC) regulations in Canada and litigation arising from patent linkage systems around the world.
Christoph Rehfuess
Head of IP
Sotio
Philip Caramanica
Chief IP Counsel & Deputy General Counsel
Alvotech
Dr. Leslie Fischer
Principal Patent Attorney
Sandoz
Leslie Fischer is a Principal Patent Attorney at Sandoz, who focuses on global IP strategy for biosimilars. Before joining Sandoz, Leslie was a patent attorney at Novartis Pharmaceuticals, where she worked for over a decade developing global patent portfolios for biologicals. Before joining the Novartis group, Leslie was an associate at Fitzpatrick Cella (NY) (now Venable). Leslie holds a J.D. from Rutgers University and a Ph.D. in Biochemistry from Thomas Jefferson University. Her scientific work appears in JCB, JBC, and Osteoarthritis & Cartilage. She speaks frequently at patent-related events and is an adjunct professor at Seton Hall Law School.
Christof Bull
Associate General Patent Counsel
UCB
Mathilde Rauline
Head of Greater Europe Patent Litigation
Sanofi
Mathilde is a European patent attorney, is qualified as a French patent attorney, and is admitted to the Paris bar.
She is head of Greater Europe patent litigation at Sanofi, after having been a patent litigator in private practice (mostly in the pharmaceutical field), and a patent attorney in the industry (Sanofi, Nestlé).
She has extensive experience in pharmaceutical and life-science patent litigation in France, at the EPO, in Europe, and in Eurasia.
Her expertise also comprises contractual matters, settlements, regulatory aspects, and the SPC regulation.
Lorenz Kallenbach
Senior Corporate Patent Counsel (Director)
Merck
Lorenz Kallenbach is a senior corporate patent counsel in the healthcare division of Merck KGaA. He is responsible for defining and executing the IP strategy for innovator projects. Including the assessment of the IP landscape, coordination of worldwide patent litigation, and portfolio development.
Before joining Merck, Lorenz worked in private practice. He is qualified as a German and European patent attorney.
Lorenz studied biochemistry and received a Ph.D. in the field of epigenetics.
Stephan Kutik
Senior Director, Intellectual Property
Genevant Sciences GmbH
Ewan Nettleton
Principal IP Counsel, Oncology Litigation
Novartis Pharma AG
Tessa M. Malamud-Cohen
Director, Patents, Global Intellectual Property
Ferring Pharmaceuticals
Paki Banky
Senior IP Counsel (IP Lead Cell & Gene)
Novartis
Corinna Sundermann
Senior Vice President Intellectual Property
Fresenius Kabi
Frank Landolt
Chief Counsel IP & Legal
Confo Therapeutics
Frank Landolt is Chief Counsel, Intellectual Property and Legal at Confo Therapeutics, a privately held biopharmaceutical start-up based in Ghent, Belgium specializing in GPCR-targeted therapeutics.
After studying chemistry and law at the University of Leiden in the Netherlands, Frank worked for almost ten years on pharmaceutical and biotechological patents and licensing in private practice in the Netherlands, where his clients included major pharmaceutical companies as well as some of the top biotech firms and research institutions in the Netherlands.
Prior to joining Confo in 2018, Frank worked for fifteen years in Ablynx N.V. (now a wholly owned Sanofi company), where he was a member of the management team and headed an integrated IP and legal group of four lawyers and five patent professionals. At Ablynx, Frank was involved in negotiating Ablynx’s strategic partnerships and licensing deals with AbbVie, Boehringer-Ingelheim, MSD, Merck-Serono, Novartis, Novo Nordisk, Sanofi and Wyeth.
From 2000 to 2004, Frank was director of IP and legal counsel at Devgen N.V. (now part of Syngenta), another Ghent-based biotechnology company, where he was involved in negotiating Devgen’s strategic collaborations with Sumitomo, Monsanto and DuPont Pioneer.
Frank is a Dutch and European patent attorney, and also holds a degree in business law from the University of Antwerp. He is a member of the Dutch association of patent attorneys (where he is a tutor for the professional qualification course), EPI and LES Benelux (where he is involved in the LES Licensing Course). He is a regular speaker on a range of topics relating to IP and licensing in the (bio)pharmaceutical sector. Frank was named as one of Managing IP’s ‘Corporate IP stars’ for four years in a row (2015-2018).
Guido Pontremoli
Vice President Global IP
Chiesi
Currently employed as global Head of the IP department-Patent at Chiesi Farmaceutici SpA, managing and coaching a team of experienced patent attorneys, patent searchers and administrators, working on the protection, enforcement, litigation and/or opposition of the Chiesi IP, aligned with business decisions.
Before joining Chiesi, I worked in IP groups of big pharma companies (GSK Vaccine, and Bracco Imaging) as senior patent attorney responsible for all the IP aspects concerning some key R&D projects. I also had experience as patent counsel in private practices, dealing with pharma, chemical and bio entities.
Graduated in chemistry from the Univ of Milan, with a PhD in medicinal chemistry and a post-doc experience in USA, I am qualified EPA and chartered Italian patent attorney.
Kristin Cooklin
Group Head IP Counsel
Recordati
Toni Santamaria
Vice President Intellectual Property
Adalvo
Toni has been leading the Intellectual Property team at Adalvo since 2021. He has more than 20 years of experience in different pharmaceutical companies where he has been involved in developing and implementing complex patent and data exclusivity litigation strategies for several generics and added value products, including leading parallel litigation cases in multiple European countries. He also has experience in patent and trademark prosecution.
Toni qualified as European Patent Attorney in 2010 and holds a PhD in Organic Chemistry.
Shohta Ueno
Assistant General Counsel - Dispute Resolution
Regeneron
Adrian Spillmann
Director of Intellectual Property
Valneva
Julia Pike
Global Head of IP
Sandoz
Since March 2020, Julia has been the Global Head of IP for Sandoz. In her previous roles with Sandoz, she has had a leading role in the first wave of US biosimilars litigation, including the first litigations on critical aspects of the governing legislation (the Biologics Price Competition and Innovation Act or BPCIA), culminating in the landmark US Supreme Court decision, Sandoz v Amgen.
Since leaving private practice at Corrs Chambers Westgarth, Julia has been in-house counsel for many years including at Mayne Pharma and Hospira Inc before joining Sandoz in 2008. While there, she has taken on roles in European public affairs and led Sandoz’s global IP litigation function as Global Head of IP Litigation. Through those roles, she has maintained a keen interest in IP strategy and litigation worldwide, including cases arising under the Hatch-Waxman and BPCIA legislation in the US, PM(NOC) regulations in Canada and litigation arising from patent linkage systems around the world.
Christoph Rehfuess
Head of IP
Sotio
Philip Caramanica
Chief IP Counsel & Deputy General Counsel
Alvotech
Register Your Interest for 2025
5 Reasons To Download The Agenda:
Explore In-House Insights: Discover the valuable perspectives from leading companies such as Astellas, UCB, Sandoz, Novartis, Chiesi, Fresenius Kabi, and MSD, delivered directly by our distinguished in-house speaking faculty.
Engage in Targeted Sessions: Dive into the most pressing pharma and biotech patent litigation topics, including preliminary injunctions (PIs), the Unified Patent Court (UPC), competition law, Supplementary Protection Certificates (SPCs), and biosimilars.
- Network with Top Firms: Gain insights from a diverse range of international and boutique patent litigation firms, participating as panellists and speakers, to enhance your understanding of the global litigation landscape.
- Tailor Your Strategy: Benefit from our new and improved tracked sessions on day 2, focusing on MedTech, small molecules, and large molecules, allowing you to craft a more personalized and effective patent litigation strategy.
- Hear from Key Decision-Makers: Learn directly from judicial and institutional speakers providing firsthand updates from critical bodies such as the UPC, UK courts, WIPO, EFPIA, the European Commission, and Medicines for Europe.
Download Full Agenda
A Snippet Of Our Private Practice Speaker Faculty
Paul Inman
PartnerGowling
Eleanor Root
PartnerBird & Bird
Rob Cerwinski
PartnerGemini Law
Luca Pellicciari
PartnerTrevisan & Cuonzo
Daan De Lange
PartnerBrinkhof
Cecile Goy
PartnerAramis Law
Naomi Pearce
CEO and LawyerPearce IP
Agathe Michel-De-Cazotte
PartnerCarpmaels & Ransford
Tjibbe Douma
Partner, IP, AmsterdamBird & Bird
Peter van Schijndel
PartnerHoyng Rokh Monegier
Benjamin May
PartnerAramis
Otto Swens
PartnerVondst
Oya Yalvac
PartnerDERIS
Denis Schertenleib
PartnerSchertenleib Avocats
Our 2024 Speakers
Agathe Michel-De-Cazotte
Partner
Carpmaels & Ransford
Andras Kupecz
Honourable Judge
UPC Munich Central Division
Andrew Hutchinson
Partner
Simmons & Simmons
Beat Weibel
Chief IP Counsel
Siemens
Beatriz Diaz de Escauriaza
Head of IP Legal
Insud Pharma
Carsten Richter
Head of IP
Euroimmun
Cecile Teles
Head of IP
Zentiva
Cecile is Head Patent Attorney at Zentiva. She has over a decade of experience in the pharmaceutical industry.
Cecile is uniquely experienced and knowledgeable in the pharma space as she has experience in-house at an elite innovator company (Sanofi), biologics (Merck Serono), and extensive generic experience she gained as Zentiva.
Cecile is an enthusiastic manager of her team and was a key member of the IP team in leading the transformation of Zentiva into an independent and competitive generic company after divestment from Sanofi.
Cecile is a qualified European Patent Attorney. She also holds a certificate from CEIPI in patent litigation and most recently completed her diploma as a Master of Laws in France.
Christoph Rehfuess
Head of IP
Sotio
Christopher Sharp
Partner
Pinsent Masons
Clemens Heusch
Head of Global Disputes and Resolution
Nokia
Conrad Eckhardt
Vice President IP
Biotronik
Conrad practices in the IP field for more than 20 years and gained experience across various industries. Having started with Consumer Products at Procter & Gamble he moved on to Pharmaceuticals at Boehringer Ingelheim and is now active in the medical device field, first as Chief IP Counsel at Leica Biosystems and currently as Chief IP Counsel at Biotronik. Conrad is a European Patent Attorney and a European Patent Litigator and has patent litigation experience in Germany, the USA and China.
Edgar Brinkman
Honourable Judge
UPC Local Division Hague
Mr. Brinkman finished a chemistry degree in 1993, specialising in biochemistry, and law degree in 1995 at Utrecht University in The Netherlands. After joining the bar that same year as a solicitor/barrister in Amsterdam focusing on patents and regulatory affairs, he was appointed judge at the Court of The Hague, IP department in 2002. He became a senior judge in 2007. He has been involved in many patent and other IP cases and speaks regularly on international conferences. He is co-editor of a leading Dutch IP magazine (BIE).
Eleanor Root
Partner
Bird & Bird
Emily Bottle
Leadership Committee
ChIPs
Filip De Corte
Head of IP
Syngenta
Filip De Corte is Head of Intellectual Property at Syngenta Crop Protection, leading patent attorneys based in Switzerland, the UK, the US, The Netherlands and China. Filip joined Syngenta on October 1, 2013. Until then, he held the position of Chief IP Counsel Europe at Cargill (2008 – 2013). Before joining Cargill in 2008, he worked in the Johnson & Johnson patent department, working in Beerse with Janssen Pharmaceutica (1991-2004), New Brunswick (2004-2007), and Brussels (2007-2008). Filip has a Ph.D. in organic chemistry, he is a qualified European Patent Attorney and passed the US patent bar exam. He has the qualification of European Patent Litigation from the University of Strasbourg. He also has an MBA of the Vlerick School of Management. Filip taught patent law in Antwerp under the auspices of CEIPI (Université de Strasbourg) as well as at the University of Leuven in the IPR management course and is a lecturer in the CEIPI patent litigation course.
Filipe Pedro
Director of IP
BIAL
Frank Landolt
Chief Counsel IP & Legal
Confo Therapeutics
Frank Landolt is Chief Counsel, Intellectual Property and Legal at Confo Therapeutics, a privately held biopharmaceutical start-up based in Ghent, Belgium specializing in GPCR-targeted therapeutics.
After studying chemistry and law at the University of Leiden in the Netherlands, Frank worked for almost ten years on pharmaceutical and biotechological patents and licensing in private practice in the Netherlands, where his clients included major pharmaceutical companies as well as some of the top biotech firms and research institutions in the Netherlands.
Prior to joining Confo in 2018, Frank worked for fifteen years in Ablynx N.V. (now a wholly owned Sanofi company), where he was a member of the management team and headed an integrated IP and legal group of four lawyers and five patent professionals. At Ablynx, Frank was involved in negotiating Ablynx’s strategic partnerships and licensing deals with AbbVie, Boehringer-Ingelheim, MSD, Merck-Serono, Novartis, Novo Nordisk, Sanofi and Wyeth.
From 2000 to 2004, Frank was director of IP and legal counsel at Devgen N.V. (now part of Syngenta), another Ghent-based biotechnology company, where he was involved in negotiating Devgen’s strategic collaborations with Sumitomo, Monsanto and DuPont Pioneer.
Frank is a Dutch and European patent attorney, and also holds a degree in business law from the University of Antwerp. He is a member of the Dutch association of patent attorneys (where he is a tutor for the professional qualification course), EPI and LES Benelux (where he is involved in the LES Licensing Course). He is a regular speaker on a range of topics relating to IP and licensing in the (bio)pharmaceutical sector. Frank was named as one of Managing IP’s ‘Corporate IP stars’ for four years in a row (2015-2018).
Gabriele Mohsler
VP Patent Development
Ericsson
Gianluca Vassallo
Case Handler, DG Competition
European Commission
Guido Pontremoli
Vice President Global IP
Chiesi
Currently employed as global Head of the IP department-Patent at Chiesi Farmaceutici SpA, managing and coaching a team of experienced patent attorneys, patent searchers and administrators, working on the protection, enforcement, litigation and/or opposition of the Chiesi IP, aligned with business decisions.
Before joining Chiesi, I worked in IP groups of big pharma companies (GSK Vaccine, and Bracco Imaging) as senior patent attorney responsible for all the IP aspects concerning some key R&D projects. I also had experience as patent counsel in private practices, dealing with pharma, chemical and bio entities.
Graduated in chemistry from the Univ of Milan, with a PhD in medicinal chemistry and a post-doc experience in USA, I am qualified EPA and chartered Italian patent attorney.
Heike Wollgast
WIPO
Ina Buerck
Senior Counsel
Amgen
James Horgan
Assistant General Counsel
MSD
Jiri Slavik
Director of IP
Adalvo
Juliane Buchinski
Lead IP Litigation Counsel
ZTE
Karin Pramberger
Head of IP
Polpharma Group
Karin has been Intellectual Property Director at the Polpharma Group since April 2018. She is responsible for all patent and trade mark related activities. Prior to joining the Polpharma Group, Karin was Head of IP of Medichem, Spain, and worked in various positions within the patent department of Teva, Barr and Pliva. She spent 7 years in a law firm in Vienna, Austria, where she became European and Austrian patent and trade mark attorney. She studied Biotechnology in Vienna, Austria, and at the Ecole Nationale Supérieure de Chemie de Paris, France. In 2017 she graduated with an LLB from the University of London. Since 2005 she has been a tutor at CEIPI, University of Strasbourg, for the pre-exam and the C-part of the European Qualifying Exam.
Katie Coltart
Partner
Linklaters
Kristin Cooklin
Group Head IP Counsel
Recordati
Laila Beynon
AD- Dispute Resolution
Regeneron
Laila Beynon is Director, Dispute Resolution at Regeneron, responsible for the strategic co-ordination of ex-US patent litigation. She has a PhD in Biochemistry/Molecular Biology, 10 years’ private practice experience in life sciences patent litigation at Herbert Smith Freehills LLP, and prior to her role at Regeneron headed up the Patent Litigation team at BAT.
Margot Kokke
Honourable Judge, Local Division Hague
UPC
Mathias Zigann, Honourable Judge, UPC- Munich
Honourable Judge
UPC- Munich
Matthew O’Neill
Director of European IP
Glenmark Pharmaceuticals
Michael Swita
Director of Intellectual Property Policy
EFPIA
Mirna Atallah
Senior Director IP
Astellas Europe
Natalia Wright
Assistant General Patent Counsel
UCB
Philippe Bessiere
Global Head of Patents
Pierre Fabre Group
Raquel Frisardi
Senior Corporate Counsel
Novo Nordisk
Rob Rodrigues
Partner
RNA law
Ronny Thomas
Honourable Judge
UPC Local Division, Dusseldorf
Sara Burghart
Senior Counsel- Patent Litigation
BAT
Sean Alexander
Head of IP Strategy
Umicore
Sean Alexander is a qualified European Patent Attorney as well as a Canadian and U.S. Patent Agent. He has worked in the IP field for many years and is currently the Head of IP Strategy (H&N) for Chr. Hansen in Denmark. Prior to joining Chr. Hansen, Sean headed the IP team at Elanco Inc. based in the Netherlands and was a Partner with Gowling WLG in Canada. Sean has been recognized as one of the world's leading IP strategists by IAM Magazine and is regularly praised for his pragmatic and commercially aware approach to IP.
Sergio Napolitano
General Counsel
Medicines for Europe
Shohta Ueno
Assistant General Counsel - Dispute Resolution
Regeneron
Stefan Luginbuehl
Head of Department European Legal Affairs
European Patent Office (EPO)
Stefan Luginbuehl, PhD, lawyer, is Head of the Department European Legal Affairs (Dep 5222) at the European Patent Office where he is dealing with a wide range of patent law and patent litigation related subjects, with emphasis on the implementation of the EU unitary patent package into the existing European patent system.
He participated in several Diplomatic and Intergovernmental Conferences on the reform of the European patent system and the international litigation system. He is a lecturer in different universities and is the author and editor of several books and articles on patent procedure and patent litigation in Europe and China.
Stefanie Kies
Senior Director Intellectual Property
Polpharma Biologics
Sufiyah Sulaiman
Senior Patent Manager Patent Litigation
STADA
Sufiyah Sulaiman is an attorney-at-law with a master’s degree in science. As an in-house patent litigation counsel of generic pharma giants, she has been managing their patent litigation and product launch-at-risk globally. At the moment, she is a senior manager (patent litigation) at STADA (Arzneimittel) AG, before that she was the Global IP litigation counsel for Sandoz (International GmbH) and, IP and regulatory litigation counsel for Mylan (now Viatris).
Tess Waldron
Leadership Committeee
ChIPs
Tjibbe Douma
Partner, IP, Amsterdam
Bird & Bird
Toni Santamaria
Vice President Intellectual Property
Adalvo
Toni has been leading the Intellectual Property team at Adalvo since 2021. He has more than 20 years of experience in different pharmaceutical companies where he has been involved in developing and implementing complex patent and data exclusivity litigation strategies for several generics and added value products, including leading parallel litigation cases in multiple European countries. He also has experience in patent and trademark prosecution.
Toni qualified as European Patent Attorney in 2010 and holds a PhD in Organic Chemistry.
Testimonials From 2024 Attendees
The Pharma/Biotech Patent Litigation Europe Conference was very informative and offered many opportunities for networking with relevant contacts.
Victoria Flowers, Executive Director Forensics, Mazars
Brilliantly organised event, great mix of practice and industry attendees, a highly relevant and useful series of panel talks, and a good balance of networking and content.
Michael Lee, Senior Director of Patents, Norgine
Two inspiring days! Once again attending this conference proved to be to be a unique opportunity not only to see colleagues and friends from all over the world and for new connections, but also to catch up and discuss with them the latest developments in current topics in pharma and biotech patent litigation.
Maria Balestriero, IP Lawyer, Portolano Cavallo
Interesting presentations and many good discussions that are both informative and thought provoking
Adrian Spillman, Director IP, Valneva Group
Great and actual topics, presentations from all kinds of different angles, open discussions, new insights. All in all very well organised!
Dominique van De Kamp, Vice President of Intellectual Property Litigation and European Patent Attorney, Synthon
Great event delivering valuable insight from all aspects of the pharma sector! Definitely the go to IP litigation conference this year!
Delicia Clarke, Legal Consultant, Regeneron Pharmaceuticals
Very stimulating event, relevant topics, good panels, lively discussions.
Beatrix Otte, Head of IP, Tillotts Pharmaceuticals
The event this year was well attended and thought provoking.
Jennifer Sunderland, Senior Patent Litigation Counsel, Mylan
Our 2025 Partners
Interested in how you can get involved with Pharma & Biotech Patent Litigation 2025?
Based on your objectives, we can create bespoke packages for you. From presenting your expertise on stage to partnering with us to deliver networking activities. Partner with us in 2025 to showcase your brand and make valuable new connections. Opportunities include thought leadership, branding, and networking.
Discuss your objectives with Duncan Henderson, Commercial Partnerships Director, [email protected]
Package
Sending Your Team? Group Discounts Available!
Applicable for Primary Market, Service Provider and Industry Rates Only. Not available for Academic or ‘Start-Up’ rates
Book a Team of 3+ - Save an Additional 10% Off
Book a Team of 5+ - Save an Additional 15% Off
If you would like to register a team of 3 or more, please email [email protected] for your discount coupon code before registering. PLEASE NOTE: Discounts cannot be combined with Early Bird Pricing or any other discount or offer. If you have any questions about your registration, please call us on +44 (0)20 3696 2920
We accept the following cards through Stripe:
Ticket price will increase in
— —
- Saturday, August 19, 2023 to Friday, October 4, 2024Tier 1 - In-House€699Super Super Early Bird rate (Register Before 4th October & Save €600)Exclusively for Pharma and Biotech2 Day In-Person Conference PassYou can add our pre-day event as an add-on during registration
- Saturday, October 5, 2024 to Friday, November 1, 2024Tier 1 - In-House€899Super Early Bird rate (Register Before 1 November & Save €400)Exclusively for Pharma and Biotech2 Day In-Person Conference PassYou can add our pre-day event as an add-on during registration
- Saturday, November 2, 2024 to Friday, December 6, 2024Tier 1 - In-House€1099Early Bird rate (Register Before 6 December & Save €200)Exclusively for Pharma and Biotech2 Day In-Person Conference PassYou can add our pre-day event as an add-on during registration
- Saturday, December 7, 2024 to Wednesday, January 22, 2025Tier 1 - In-House€1299Standard RateExclusively for Pharma and Biotech2 Day In-Person Conference PassYou can add our pre-day event as an add-on during registration
- Saturday, August 19, 2023 to Friday, October 4, 2024Tier 2 - Law Firms€1999Super Super Early Bird rate (Register Before 4th October & Save €1000)Exclusively for Law firms focusing on Life Sciences & Intellectual Properties Providers Pricing2 Day In-Person Conference PassYou can add our pre-event workshop as an add-on during registration
- Saturday, October 5, 2024 to Friday, November 1, 2024Tier 2 - Law Firms€2399Super Early Bird rate (Register Before 1 November & Save €600)Exclusively for Law firms focusing on Life Sciences & Intellectual Properties Providers Pricing2 Day In-Person Conference PassYou can add our pre-event workshop as an add-on during registration
- Saturday, November 2, 2024 to Friday, December 6, 2024Tier 2 - Law Firms€2599Early Bird rate (Register Before 6 Decemeber & Save €400)Exclusively for Law firms focusing on Life Sciences & Intellectual Properties Providers Pricing2 Day In-Person Conference PassYou can add our pre-event workshop as an add-on during registration
- Saturday, December 7, 2024 to Wednesday, January 22, 2025Tier 2 - Law Firms€2999Standard Rate
- Sunday, August 13, 2023 to Friday, October 4, 2024Tier 3 - Vendors€2099Super Super Early Bird rate (Register Before 4th October & Save €1400)Exclusively for Solution Providers2 Day In-Person Conference PassYou can add our pre-event workshop as an add-on during registration
- Saturday, October 5, 2024 to Friday, November 1, 2024Tier 3 - Vendors€2499Super Early Bird rate (Register Before 1 November & Save €1000)Exclusively for Solution Providers2 Day In-Person Conference PassYou can add our pre-event workshop as an add-on during registration
- Saturday, November 2, 2024 to Friday, December 6, 2024Tier 3 - Vendors€2999Early Bird rate (Register Before 6 December & Save €500)Exclusively for Solution Providers2 Day In-Person Conference PassYou can add our pre-event workshop as an add-on during registration
- Saturday, December 7, 2024 to Wednesday, January 22, 2025Tier 3 - Vendors€3499Standard RateExclusively for Solution Providers2 Day In-Person Conference PassYou can add our pre-event workshop as an add-on during registration
- Friday, July 28, 2023 to Monday, January 22, 2024UPC Forum 2024 (22 January)€899Develop a Pan-European litigation strategy Industry-led panel sessions focusing patent value and the UPC from a cross-industry perspectiveUnderstand the decision making process of the people behind the new system with a cross-industry judicial panel sessionGain a practical and in-depth understanding of UPC litigation practice with a mock trial focusing on the central themes of the new court
Preparing registration...
Life Sciences Patent Advisory Board
Dr. Leslie Fischer
Principal Patent Attorney
Sandoz
Leslie Fischer is a Principal Patent Attorney at Sandoz, who focuses on global IP strategy for biosimilars. Before joining Sandoz, Leslie was a patent attorney at Novartis Pharmaceuticals, where she worked for over a decade developing global patent portfolios for biologicals. Before joining the Novartis group, Leslie was an associate at Fitzpatrick Cella (NY) (now Venable). Leslie holds a J.D. from Rutgers University and a Ph.D. in Biochemistry from Thomas Jefferson University. Her scientific work appears in JCB, JBC, and Osteoarthritis & Cartilage. She speaks frequently at patent-related events and is an adjunct professor at Seton Hall Law School.
Christof Bull
Assistant General Patent Counsel
UCB
Lorenz Kallenbach
Senior Corporate Patent Counsel (Director)
Merck
Lorenz Kallenbach is a senior corporate patent counsel in the healthcare division of Merck KGaA. He is responsible for defining and executing the IP strategy for innovator projects. Including the assessment of the IP landscape, coordination of worldwide patent litigation, and portfolio development.
Before joining Merck, Lorenz worked in private practice. He is qualified as a German and European patent attorney.
Lorenz studied biochemistry and received a Ph.D. in the field of epigenetics.
Stephan Kutik
Senior Director, Intellectual Property
Genevant Sciences GmbH
Ewan Nettleton
Principal IP Counsel, Oncology Litigation
Novartis Pharma AG
Tessa M. Malamud-Cohen
Director, Patents, Global Intellectual Property
Ferring Pharmaceuticals
Paki Banky
Senior IP Counsel (IP Lead Cell & Gene)
Novartis
Corinna Sundermann
Senior Vice President Intellectual Property
Fresenius Kabi
Frank Landolt
Chief Counsel IP & Legal
Confo Therapeutics
Frank Landolt is Chief Counsel, Intellectual Property and Legal at Confo Therapeutics, a privately held biopharmaceutical start-up based in Ghent, Belgium specializing in GPCR-targeted therapeutics.
After studying chemistry and law at the University of Leiden in the Netherlands, Frank worked for almost ten years on pharmaceutical and biotechological patents and licensing in private practice in the Netherlands, where his clients included major pharmaceutical companies as well as some of the top biotech firms and research institutions in the Netherlands.
Prior to joining Confo in 2018, Frank worked for fifteen years in Ablynx N.V. (now a wholly owned Sanofi company), where he was a member of the management team and headed an integrated IP and legal group of four lawyers and five patent professionals. At Ablynx, Frank was involved in negotiating Ablynx’s strategic partnerships and licensing deals with AbbVie, Boehringer-Ingelheim, MSD, Merck-Serono, Novartis, Novo Nordisk, Sanofi and Wyeth.
From 2000 to 2004, Frank was director of IP and legal counsel at Devgen N.V. (now part of Syngenta), another Ghent-based biotechnology company, where he was involved in negotiating Devgen’s strategic collaborations with Sumitomo, Monsanto and DuPont Pioneer.
Frank is a Dutch and European patent attorney, and also holds a degree in business law from the University of Antwerp. He is a member of the Dutch association of patent attorneys (where he is a tutor for the professional qualification course), EPI and LES Benelux (where he is involved in the LES Licensing Course). He is a regular speaker on a range of topics relating to IP and licensing in the (bio)pharmaceutical sector. Frank was named as one of Managing IP’s ‘Corporate IP stars’ for four years in a row (2015-2018).
Guido Pontremoli
Vice President Global IP
Chiesi
Currently employed as global Head of the IP department-Patent at Chiesi Farmaceutici SpA, managing and coaching a team of experienced patent attorneys, patent searchers and administrators, working on the protection, enforcement, litigation and/or opposition of the Chiesi IP, aligned with business decisions.
Before joining Chiesi, I worked in IP groups of big pharma companies (GSK Vaccine, and Bracco Imaging) as senior patent attorney responsible for all the IP aspects concerning some key R&D projects. I also had experience as patent counsel in private practices, dealing with pharma, chemical and bio entities.
Graduated in chemistry from the Univ of Milan, with a PhD in medicinal chemistry and a post-doc experience in USA, I am qualified EPA and chartered Italian patent attorney.
Kristin Cooklin
Group Head IP Counsel
Recordati
Toni Santamaria
Vice President Intellectual Property
Adalvo
Toni has been leading the Intellectual Property team at Adalvo since 2021. He has more than 20 years of experience in different pharmaceutical companies where he has been involved in developing and implementing complex patent and data exclusivity litigation strategies for several generics and added value products, including leading parallel litigation cases in multiple European countries. He also has experience in patent and trademark prosecution.
Toni qualified as European Patent Attorney in 2010 and holds a PhD in Organic Chemistry.
Shohta Ueno
Assistant General Counsel - Dispute Resolution
Regeneron
Adrian Spillmann
Director of Intellectual Property
Valneva
Julia Pike
Global Head of IP
Sandoz
Since March 2020, Julia has been the Global Head of IP for Sandoz. In her previous roles with Sandoz, she has had a leading role in the first wave of US biosimilars litigation, including the first litigations on critical aspects of the governing legislation (the Biologics Price Competition and Innovation Act or BPCIA), culminating in the landmark US Supreme Court decision, Sandoz v Amgen.
Since leaving private practice at Corrs Chambers Westgarth, Julia has been in-house counsel for many years including at Mayne Pharma and Hospira Inc before joining Sandoz in 2008. While there, she has taken on roles in European public affairs and led Sandoz’s global IP litigation function as Global Head of IP Litigation. Through those roles, she has maintained a keen interest in IP strategy and litigation worldwide, including cases arising under the Hatch-Waxman and BPCIA legislation in the US, PM(NOC) regulations in Canada and litigation arising from patent linkage systems around the world.
Christoph Rehfuess
Head of IP
Sotio
Dr. Leslie Fischer
Principal Patent Attorney
Sandoz
Leslie Fischer is a Principal Patent Attorney at Sandoz, who focuses on global IP strategy for biosimilars. Before joining Sandoz, Leslie was a patent attorney at Novartis Pharmaceuticals, where she worked for over a decade developing global patent portfolios for biologicals. Before joining the Novartis group, Leslie was an associate at Fitzpatrick Cella (NY) (now Venable). Leslie holds a J.D. from Rutgers University and a Ph.D. in Biochemistry from Thomas Jefferson University. Her scientific work appears in JCB, JBC, and Osteoarthritis & Cartilage. She speaks frequently at patent-related events and is an adjunct professor at Seton Hall Law School.
Christof Bull
Assistant General Patent Counsel
UCB
Lorenz Kallenbach
Senior Corporate Patent Counsel (Director)
Merck
Lorenz Kallenbach is a senior corporate patent counsel in the healthcare division of Merck KGaA. He is responsible for defining and executing the IP strategy for innovator projects. Including the assessment of the IP landscape, coordination of worldwide patent litigation, and portfolio development.
Before joining Merck, Lorenz worked in private practice. He is qualified as a German and European patent attorney.
Lorenz studied biochemistry and received a Ph.D. in the field of epigenetics.
Stephan Kutik
Senior Director, Intellectual Property
Genevant Sciences GmbH
Ewan Nettleton
Principal IP Counsel, Oncology Litigation
Novartis Pharma AG
Tessa M. Malamud-Cohen
Director, Patents, Global Intellectual Property
Ferring Pharmaceuticals
Paki Banky
Senior IP Counsel (IP Lead Cell & Gene)
Novartis
Corinna Sundermann
Senior Vice President Intellectual Property
Fresenius Kabi
Frank Landolt
Chief Counsel IP & Legal
Confo Therapeutics
Frank Landolt is Chief Counsel, Intellectual Property and Legal at Confo Therapeutics, a privately held biopharmaceutical start-up based in Ghent, Belgium specializing in GPCR-targeted therapeutics.
After studying chemistry and law at the University of Leiden in the Netherlands, Frank worked for almost ten years on pharmaceutical and biotechological patents and licensing in private practice in the Netherlands, where his clients included major pharmaceutical companies as well as some of the top biotech firms and research institutions in the Netherlands.
Prior to joining Confo in 2018, Frank worked for fifteen years in Ablynx N.V. (now a wholly owned Sanofi company), where he was a member of the management team and headed an integrated IP and legal group of four lawyers and five patent professionals. At Ablynx, Frank was involved in negotiating Ablynx’s strategic partnerships and licensing deals with AbbVie, Boehringer-Ingelheim, MSD, Merck-Serono, Novartis, Novo Nordisk, Sanofi and Wyeth.
From 2000 to 2004, Frank was director of IP and legal counsel at Devgen N.V. (now part of Syngenta), another Ghent-based biotechnology company, where he was involved in negotiating Devgen’s strategic collaborations with Sumitomo, Monsanto and DuPont Pioneer.
Frank is a Dutch and European patent attorney, and also holds a degree in business law from the University of Antwerp. He is a member of the Dutch association of patent attorneys (where he is a tutor for the professional qualification course), EPI and LES Benelux (where he is involved in the LES Licensing Course). He is a regular speaker on a range of topics relating to IP and licensing in the (bio)pharmaceutical sector. Frank was named as one of Managing IP’s ‘Corporate IP stars’ for four years in a row (2015-2018).
Guido Pontremoli
Vice President Global IP
Chiesi
Currently employed as global Head of the IP department-Patent at Chiesi Farmaceutici SpA, managing and coaching a team of experienced patent attorneys, patent searchers and administrators, working on the protection, enforcement, litigation and/or opposition of the Chiesi IP, aligned with business decisions.
Before joining Chiesi, I worked in IP groups of big pharma companies (GSK Vaccine, and Bracco Imaging) as senior patent attorney responsible for all the IP aspects concerning some key R&D projects. I also had experience as patent counsel in private practices, dealing with pharma, chemical and bio entities.
Graduated in chemistry from the Univ of Milan, with a PhD in medicinal chemistry and a post-doc experience in USA, I am qualified EPA and chartered Italian patent attorney.
Kristin Cooklin
Group Head IP Counsel
Recordati
Toni Santamaria
Vice President Intellectual Property
Adalvo
Toni has been leading the Intellectual Property team at Adalvo since 2021. He has more than 20 years of experience in different pharmaceutical companies where he has been involved in developing and implementing complex patent and data exclusivity litigation strategies for several generics and added value products, including leading parallel litigation cases in multiple European countries. He also has experience in patent and trademark prosecution.
Toni qualified as European Patent Attorney in 2010 and holds a PhD in Organic Chemistry.
Shohta Ueno
Assistant General Counsel - Dispute Resolution
Regeneron
Adrian Spillmann
Director of Intellectual Property
Valneva
Julia Pike
Global Head of IP
Sandoz
Since March 2020, Julia has been the Global Head of IP for Sandoz. In her previous roles with Sandoz, she has had a leading role in the first wave of US biosimilars litigation, including the first litigations on critical aspects of the governing legislation (the Biologics Price Competition and Innovation Act or BPCIA), culminating in the landmark US Supreme Court decision, Sandoz v Amgen.
Since leaving private practice at Corrs Chambers Westgarth, Julia has been in-house counsel for many years including at Mayne Pharma and Hospira Inc before joining Sandoz in 2008. While there, she has taken on roles in European public affairs and led Sandoz’s global IP litigation function as Global Head of IP Litigation. Through those roles, she has maintained a keen interest in IP strategy and litigation worldwide, including cases arising under the Hatch-Waxman and BPCIA legislation in the US, PM(NOC) regulations in Canada and litigation arising from patent linkage systems around the world.
Christoph Rehfuess
Head of IP
Sotio
IN PARTNERSHIP WITH
Platinum Partners
Fish & Richardson
Website: https://www.fr.com/industries/life-sciences/
Fish & Richardson has represented pioneering life science innovators from our earliest days. We work closely with life sciences companies to help them achieve their strategic IP goals through acquisition, partnering, licensing, financing, and enforcement. We do this by bringing a unique holistic approach to our clients’ IP matters, fostered by the collaboration between our patent prosecution, litigation, and regulatory practices. We have helped our clients build valuable patent portfolios worth billions of dollars, score big victories at the Patent Trial and Appeal Board (PTAB), and win bet-the-company cases in court. When life sciences clients come to Fish to build an IP strategy, they know that we will leave no stone unturned when crafting creative and comprehensive solutions to maximize the value of their IP.
Gowling WLG
Website: https://gowlingwlg.com/
With more than 1,500 legal professionals in offices worldwide, Gowling WLG offers clients a comprehensive suite of sector-focused legal services. With an award winning global intellectual property practice, our full service firm stands out for its ability to provide support for the full life cycle of a smart idea.
Trade secret protection is an important part of this offering with services spanning multiple disciplines – from the development of trade secrets and data protection policies, to the drafting of NDAs and employment contracts, through to cybersecurity risk management and high stakes litigation.
Whether you are looking to identify and protect your trade secrets to avoid leakage, establishing the value of your intangible assets for merger or acquisition or pursuing a trade secret thief, we can help guide you through trade secrets law around the world and across a number of key sectors. Learn more
Linklaters
Website: https://www.linklaters.com/
Linklaters cross-border Intellectual Property team successfully advises market-leading companies on high-profile IP litigation and complex IP-driven transactions.
We advise clients in a broad range of sectors, with a focus on IP-heavy industries such as healthcare and life sciences.
Our history of advising clients in the healthcare and life sciences sector is long and we have developed strong working relationships and a deep understanding of our client’s business environment. Many of our lawyers have technical backgrounds and therefore have in-depth understanding of complex technologies.
We support our clients with outstanding legal skills, expert sector knowledge and a pragmatic mindset in cross-border IP disputes. More specifically our litigation practice covers the full scope of dispute resolution, including court proceedings, arbitration, mediation and settlement discussions. Where possible, we aim to resolve disputes before court proceedings become necessary. However, where litigation is unavoidable, we take care to pick the right cases to pursue through the courts and continue to look for pragmatic solutions.
We tackle the entire spectrum of IP rights, including patents, supplementary protection certificates, copyrights, designs and trademarks. Our practice also covers issues of confidentiality, as well as trade secrets protection and misappropriation.
Maiwald Intellectual Property
Website: https://www.maiwald.eu/en/
As one of Germany’s largest and best-known firms in the field of intellectual property (IP), providing optimal services to our clients is of paramount importance to us. Our team comprising about 250 people in Munich and Düsseldorf works closely with each other and with foreign associates, always with an eye to the client’s particular needs, regardless of the particular industry or type of company, whether start-up, medium-sized firm or large corporation, in Germany and worldwide. We at Maiwald will do everything to ensure that all your IP matters are handled with competence and commitment.
You can rely on Maiwald’s wide-ranging expertise. We provide a full range of services covering all aspects of IP law. Our highly qualified patent attorneys and attorneys-at-law unite all of the most important skills one would expect of an interdisciplinary team: sound legal knowledge, business proficiency and a broad range of technical and scientific know-how. And, it goes without saying, absolute professionalism, efficiency and close attention to the needs of each individual client. So you may be assured of receiving the best possible advice on all IP-related issues based on our proven competence and industry knowledge.
Marks & Clerk
Website: https://www.marks-clerk.com/
Marks & Clerk is an international law firm specialising in intellectual property (IP) law. With a vast network of over 650 professionals across the world, including a qualified team of experienced patent and trademark associates, the firm offers comprehensive technical expertise covering all aspects of intellectual property matters, such as patents, trademarks, designs and copyright. Its services encompass worldwide protection, portfolio management, strategic advice, commercial guidance, licensing, enforcement, clearance and searches, validity and infringement opinions, due diligence and litigation. Operating through a network of offices in Canada, Europe and Asia, Marks & Clerk consistently delivers high-quality, seamless and cost-effective services to clients both locally and globally.
Pinsent Masons
Website: https://www.pinsentmasons.com/
Pinsent Masons international Life Sciences practice is one of the best in Europe.
Their team, comprising more than 100 sector specialists, many of whom are leading individuals in their field with relevant scientific degrees (some to Ph.D.) and experience, drawn from industry, is dedicated to helping their clients continue to develop cutting-edge strategies that use the law as a business enabler to positively impact their bottom line.
The team acts for businesses globally on complex market shifting transactions; cutting edge R&D collaboration; partnering and licensing deals; the most high profile, business-critical patent and regulatory litigations; and hugely impactful anti-trust investigations and litigations.
Comprising some of the world’s leading life sciences experts, the team works with senior management and in-house legal teams to navigate complex regulatory environments, develop effective risk management strategies, and spot and convert opportunities.
Schertenleib Avocats
Website: https://schertenleib-avocats.com/en/equipe/denis-schertenleib/
Please visit our website for more information.Gold Partners
Barnes And Thornbug LLP
Website: https://btlaw.com/
Intellectual Property
Barnes & Thornburg’s Intellectual Property Department, with more than 130 attorneys and professionals, is one of the largest intellectual property practice groups found in a full-service law firm. Our practice covers a broad spectrum of services, including strategic IP portfolio services, prosecuting and litigating patents, trademarks and copyrights, enforcement of patents and trademarks, and defense of IP enforcement actions.
Our IP practice advises and helps a diverse and multinational roster of clients. From electrical and mechanical engineering, to chemistry and microbiology, to computer technology and business methods – our attorneys’ background and experience in several technical disciplines positions us to meet a variety of sophisticated business and inventorship needs.
Life Sciences
Barnes & Thornburg provides a wide range of interdisciplinary legal services to organizations engaged in biotechnology, pharmaceuticals, medical and laboratory devices, health services and bioinformatics. Most of the lawyers in our biotech practice have educational and practical research experience pertinent to the biotechnology industry and many hold advanced degrees in organic chemistry, pharmacology, molecular biology, genetics, immunology and microbiology. We understand chemistry, biotech, pharmaceutical, and medical device technologies. In addition, our intellectual property practice includes professionals with advanced degrees in molecular biology, chemistry, organic chemistry, biochemistry, genetics, biology, pharmacology, immunology, microbiology, biotechnology, bioengineering, physics, mechanical engineering, electrical engineering, industrial engineering, and civil engineering.
Our team represents a wide array of clients in this industry – from startups to Fortune 500 companies. Some of our representative clients include 3M Company, DePuy Orthopaedics, Inc., Eli Lilly and Company, Johnson & Johnson, H.D. Smith Wholesale Drug Co., Hillenbrand, \
Carpmaels & Ransford
Website: https://www.carpmaels.com/
Carpmaels & Ransford LLP is a leader in the European IP market, having driven innovation in the industry for over 200 years. The firm advises clients on all aspects of intellectual property, including drafting, filing and prosecuting patent and trademark applications; drafting and negotiating licence agreements and other commercial IP agreements; advising on the transfer of property rights; assisting clients with patent restoration matters; and conducting enforcement and revocation litigation.
The firm has one of Europe’s largest IP teams serving blue-chip clients across the globe, including Johnson & Johnson, Bristol Myers Squibb, Novartis, Ionis Pharmaceuticals, Mars, Gilead, Raytheon, Regeneron, Takeda, Allergan and Xeros. The firm’s attorneys have considerable technical knowledge, bringing together experience from industry-leading companies, academic research at leading universities and extensive patent expertise in the areas of pharmaceuticals, biotechnology, engineering, tech, chemistry, materials, supplementary protection certificates and information and communication technologies and standards.
Through its fully integrated dispute resolution and transactions teams, the firm is able to provide a holistic service to clients which supports their IP needs from inception to commercialisation. The dispute resolution team, made up of experienced solicitors, barristers and patent attorney litigators, represents clients at all levels of the European Patent Office. The team is also adept at conducting enforcement litigation and revocation actions before the UK Intellectual Property Office and patent, copyright, trademark and other IP litigation in the English courts and the Court of Justice of the European Union, often advising in cases where parallel or related litigation is ongoing in courts across Europe or in the United States.
As a European IP firm with litigators and patent attorneys under one roof, Carpmaels & Ransford is looking forward to offering clients the chance to both obtain UPs using the existing EPO procedure and enforce their patents across Europe in the UPC.
LAVOIX
Website: https://www.lavoix.eu/en
LAVOIX, a European firm fully dedicated to Intellectual Property (IP), has close to 200 IP professionals including 80 attorneys-at-law, industrial property attorneys and technology specialists.The firm’s sheer size and the diversity of its team’s areas of expertise enable LAVOIX to assist its clients in every aspect of IP across all business areas and technological fields.
Our Life Science team has extensive technical expertise in many areas including biotechnology, pharmaceutical chemistry and bioinformatics.
Our attorneys are able to prosecute patent applications in the three European Patent Office official languages (English, German and French). Our Munich office provides direct and easy access to the EPO and the German Patent Office.
Our Life Science team is also regularly involved in oppositions, appeals and oral proceedings before the EPO, management of Supplementary Protection Certificates, as well as due diligence, precontentious opinions and national or pan-European litigations.
With a view to maximize the position of our clients and meet their specific needs, our Life Science Team also monitors the latest developments of the European Union’s law which could potentially affect our client’s businesses, in particular in respect of pharmaceuticals, chemicals, agrochemicals and medical devices.
Potter Clarkson
Website: https://www.potterclarkson.com/
Leading European intellectual property law firm, Potter Clarkson helps companies, organisations, and individuals across all sectors of business to understand, create, protect, and defend the commercial value of their innovations anywhere in the world. Its 200-strong specialist team of patent attorneys, trade mark attorneys, litigators, and licensing specialists, operate from dedicated offices in the UK, Sweden, and Denmark.
Recognised as one of Europe’s leading intellectual property law firms, Potter Clarkson is particularly well-known for its deep expertise in resolving life science disputes, its contentious practice routinely conducting high-profile litigation in key jurisdictions around the world as well as before the EPO, and now the UPC, with multiple actions currently on foot before this important new court.
Simmons & Simmons
Website: https://www.simmons-simmons.com/en/expertise/service/intellectual-property/patents
Our international Patent team seamlessly integrates the specialized expertise of a boutique practice with the extensive service offerings of a major international firm. Recognized in the market for our high-calibre clients and active involvement in leading global patent cases, we stand as a trusted force in the European legal landscape; with offices and well established patent experts in London, Amsterdam, Paris, Munich and Milan and with Pharma & Biotech as one of our firm’s four core sectors.
Leveraging our extensive experience, we adeptly guide clients through specialised procedures, including infringement seizures, preliminary injunctions, patent infringement actions, patent nullification actions, and non-infringement declarations. With over 45 years at the forefront of IP law and practice, our international reputation is anchored in a pre-eminent track record in complex patent litigation (alongside a market-leading IP transactions and regulatory practices). Our comprehensive suite of services offers a "one-stop-shop" for pharma and biotech clients needing advice and strategic partnership on patents and other areas of IP.
Simmons and Simmons has played a pivotal role in the development of the Unified Patent Court (UPC) system. Our partner, Kevin Mooney, is acknowledged as one of the "fathers of the UPC", if not “Mr UPC”. Positioned at the forefront of every aspect of the new system, we don't just advise on the law – we actively shape it.
Sterne Kessler
Website: https://www.sternekessler.com/
Please visit our website for more information.Trevisan & Cuonzo
Website: https://www.trevisancuonzo.com/en/index.html
Please visit our website for more information.Solutions Partner
RWS
Website: https://www.rws.com/intellectual-property-services/
RWS is the world’s leading provider of technology-enabled language, content management, and intellectual property services. With over 60 years of experience in the IP arena RWS expertise in patent translations, foreign filing and IP research services is unrivalled.
Clients trust RWS to deliver high-quality translations in a format ready for filing, in compliance with national filing formalities and maintaining exactly the same protective scope as the original.
RWS also helps clients simplify and streamline their internal processes, by providing flexible, cost-effective foreign filing and renewals services dramatically reducing the administrative burden associated with EP validations, PCT national phase entries and direct filings.
When it comes to research, RWS offers the most robust intellectual property (IP) researcher services and tools available. From our market leading patent research database, PatBase, to the world’s most comprehensive set of IP search offerings from desk based analysts to crowdsearch.
RWS clients include many of the world's largest filers including 19 of the top 20 applicants at the World Intellectual Property Organization and 16 of the top 20 applicants at the European Patent Office.
Founded in 1958, RWS is headquartered in the UK and publicly listed on AIM, the London Stock Exchange regulated market (RWS.L).
Lanyard Partner
Moroglu Arseven
Website: https://www.morogluarseven.com/
Please visit our website for more information.Conference Packages
Sending Your Team? Group Discounts Available!
Applicable for Primary Market, Service Provider and Industry Rates Only. Not available for Academic or ‘Start-Up’ rates
Book a Team of 3+ - Save an Additional 10% Off
Book a Team of 5+ - Save an Additional 15% Off
If you would like to register a team of 3 or more, please email [email protected] for your discount coupon code before registering. PLEASE NOTE: Discounts cannot be combined with Early Bird Pricing or any other discount or offer. If you have any questions about your registration, please call us on +44 (0)20 3696 2920
We accept the following cards through Stripe:
Ticket price will increase in
— —
- Saturday, August 19, 2023 to Friday, October 4, 2024Tier 1 - In-House€699Super Super Early Bird rate (Register Before 4th October & Save €600)Exclusively for Pharma and Biotech2 Day In-Person Conference PassYou can add our pre-day event as an add-on during registration
- Saturday, October 5, 2024 to Friday, November 1, 2024Tier 1 - In-House€899Super Early Bird rate (Register Before 1 November & Save €400)Exclusively for Pharma and Biotech2 Day In-Person Conference PassYou can add our pre-day event as an add-on during registration
- Saturday, November 2, 2024 to Friday, December 6, 2024Tier 1 - In-House€1099Early Bird rate (Register Before 6 December & Save €200)Exclusively for Pharma and Biotech2 Day In-Person Conference PassYou can add our pre-day event as an add-on during registration
- Saturday, December 7, 2024 to Wednesday, January 22, 2025Tier 1 - In-House€1299Standard RateExclusively for Pharma and Biotech2 Day In-Person Conference PassYou can add our pre-day event as an add-on during registration
- Saturday, August 19, 2023 to Friday, October 4, 2024Tier 2 - Law Firms€1999Super Super Early Bird rate (Register Before 4th October & Save €1000)Exclusively for Law firms focusing on Life Sciences & Intellectual Properties Providers Pricing2 Day In-Person Conference PassYou can add our pre-event workshop as an add-on during registration
- Saturday, October 5, 2024 to Friday, November 1, 2024Tier 2 - Law Firms€2399Super Early Bird rate (Register Before 1 November & Save €600)Exclusively for Law firms focusing on Life Sciences & Intellectual Properties Providers Pricing2 Day In-Person Conference PassYou can add our pre-event workshop as an add-on during registration
- Saturday, November 2, 2024 to Friday, December 6, 2024Tier 2 - Law Firms€2599Early Bird rate (Register Before 6 Decemeber & Save €400)Exclusively for Law firms focusing on Life Sciences & Intellectual Properties Providers Pricing2 Day In-Person Conference PassYou can add our pre-event workshop as an add-on during registration
- Saturday, December 7, 2024 to Wednesday, January 22, 2025Tier 2 - Law Firms€2999Standard Rate
- Sunday, August 13, 2023 to Friday, October 4, 2024Tier 3 - Vendors€2099Super Super Early Bird rate (Register Before 4th October & Save €1400)Exclusively for Solution Providers2 Day In-Person Conference PassYou can add our pre-event workshop as an add-on during registration
- Saturday, October 5, 2024 to Friday, November 1, 2024Tier 3 - Vendors€2499Super Early Bird rate (Register Before 1 November & Save €1000)Exclusively for Solution Providers2 Day In-Person Conference PassYou can add our pre-event workshop as an add-on during registration
- Saturday, November 2, 2024 to Friday, December 6, 2024Tier 3 - Vendors€2999Early Bird rate (Register Before 6 December & Save €500)Exclusively for Solution Providers2 Day In-Person Conference PassYou can add our pre-event workshop as an add-on during registration
- Saturday, December 7, 2024 to Wednesday, January 22, 2025Tier 3 - Vendors€3499Standard RateExclusively for Solution Providers2 Day In-Person Conference PassYou can add our pre-event workshop as an add-on during registration
- Friday, July 28, 2023 to Monday, January 22, 2024UPC Forum 2024 (22 January)€899Develop a Pan-European litigation strategy Industry-led panel sessions focusing patent value and the UPC from a cross-industry perspectiveUnderstand the decision making process of the people behind the new system with a cross-industry judicial panel sessionGain a practical and in-depth understanding of UPC litigation practice with a mock trial focusing on the central themes of the new court
Preparing registration...
About Kisaco Research
Kisaco Research produces, designs and hosts B2B industry conferences, exhibitions and communities – focused on a specialized selection of topic areas.
Meet industry peers that will help build a career-changing network for life.
Learn from the mistakes of your peers as much as their successes—ambitious industry stalwarts who are happy to share not just what has made them successful so far but also their plans for future proofing their companies.
Note down the inspired insight that will form the foundation for future strategies and roadmaps, both at our events and through our online communities.
Invest both in your company growth and your own personal development by signing up to one of our events and get started.
We'd love to hear from you.
Contact us at +44 (0)20 3696 2920 and email [email protected], or let us know what subject area you're interested in below.